172 related articles for article (PubMed ID: 24236047)
1. Zinc Finger 280B regulates sGCα1 and p53 in prostate cancer cells.
Gao S; Hsieh CL; Zhou J; Shemshedini L
PLoS One; 2013; 8(11):e78766. PubMed ID: 24236047
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylyl cyclase α1 and p53 cytoplasmic sequestration and down-regulation in prostate cancer.
Cai C; Hsieh CL; Gao S; Kannan A; Bhansali M; Govardhan K; Dutta R; Shemshedini L
Mol Endocrinol; 2012 Feb; 26(2):292-307. PubMed ID: 22174378
[TBL] [Abstract][Full Text] [Related]
3. COP9 subunits 4 and 5 target soluble guanylyl cyclase α1 and p53 in prostate cancer cells.
Bhansali M; Shemshedini L
Mol Endocrinol; 2014 Jun; 28(6):834-45. PubMed ID: 24725084
[TBL] [Abstract][Full Text] [Related]
4. Androgen regulation of soluble guanylyl cyclasealpha1 mediates prostate cancer cell proliferation.
Cai C; Chen SY; Zheng Z; Omwancha J; Lin MF; Balk SP; Shemshedini L
Oncogene; 2007 Mar; 26(11):1606-15. PubMed ID: 16964290
[TBL] [Abstract][Full Text] [Related]
5. A peptide against soluble guanylyl cyclase α1: a new approach to treating prostate cancer.
Gao S; Hsieh CL; Bhansali M; Kannan A; Shemshedini L
PLoS One; 2013; 8(5):e64189. PubMed ID: 23724033
[TBL] [Abstract][Full Text] [Related]
6. Regulation of p53 and suppression of apoptosis by the soluble guanylyl cyclase/cGMP pathway in human ovarian cancer cells.
Fraser M; Chan SL; Chan SS; Fiscus RR; Tsang BK
Oncogene; 2006 Apr; 25(15):2203-12. PubMed ID: 16288207
[TBL] [Abstract][Full Text] [Related]
7. Murine double minute 2 siRNA and wild-type p53 gene therapy interact positively with zinc on prostate tumours in vitro and in vivo.
Gu J; Wang B; Liu Y; Zhong L; Tang Y; Guo H; Jiang T; Wang L; Li Y; Cai L
Eur J Cancer; 2014 Apr; 50(6):1184-94. PubMed ID: 24447832
[TBL] [Abstract][Full Text] [Related]
8. Elevation of soluble guanylate cyclase suppresses proliferation and survival of human breast cancer cells.
Wen HC; Chuu CP; Chen CY; Shiah SG; Kung HJ; King KL; Su LC; Chang SC; Chang CH
PLoS One; 2015; 10(4):e0125518. PubMed ID: 25928539
[TBL] [Abstract][Full Text] [Related]
9. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia.
Vermeersch P; Buys E; Pokreisz P; Marsboom G; Ichinose F; Sips P; Pellens M; Gillijns H; Swinnen M; Graveline A; Collen D; Dewerchin M; Brouckaert P; Bloch KD; Janssens S
Circulation; 2007 Aug; 116(8):936-43. PubMed ID: 17679618
[TBL] [Abstract][Full Text] [Related]
10. Gender-specific hypertension and responsiveness to nitric oxide in sGCalpha1 knockout mice.
Buys ES; Sips P; Vermeersch P; Raher MJ; Rogge E; Ichinose F; Dewerchin M; Bloch KD; Janssens S; Brouckaert P
Cardiovasc Res; 2008 Jul; 79(1):179-86. PubMed ID: 18339647
[TBL] [Abstract][Full Text] [Related]
11. Oncomir miR-125b suppresses p14(ARF) to modulate p53-dependent and p53-independent apoptosis in prostate cancer.
Amir S; Ma AH; Shi XB; Xue L; Kung HJ; Devere White RW
PLoS One; 2013; 8(4):e61064. PubMed ID: 23585871
[TBL] [Abstract][Full Text] [Related]
12. RNF2/Ring1b negatively regulates p53 expression in selective cancer cell types to promote tumor development.
Su WJ; Fang JS; Cheng F; Liu C; Zhou F; Zhang J
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1720-5. PubMed ID: 23319651
[TBL] [Abstract][Full Text] [Related]
13. TRIM25 enhances cell growth and cell survival by modulating p53 signals via interaction with G3BP2 in prostate cancer.
Takayama KI; Suzuki T; Tanaka T; Fujimura T; Takahashi S; Urano T; Ikeda K; Inoue S
Oncogene; 2018 Apr; 37(16):2165-2180. PubMed ID: 29379164
[TBL] [Abstract][Full Text] [Related]
14. Peptide B targets soluble guanylyl cyclase α1 and kills prostate cancer cells.
Zhou J; Gao S; Hsieh CL; Malla M; Shemshedini L
PLoS One; 2017; 12(8):e0184088. PubMed ID: 28859127
[TBL] [Abstract][Full Text] [Related]
15. The oncoprotein HBXIP promotes human breast cancer growth through down-regulating p53 via miR-18b/MDM2 and pAKT/MDM2 pathways.
Li H; Wang Z; Jiang M; Fang RP; Shi H; Shen Y; Cai XL; Liu Q; Ye K; Fan SJ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2018 Nov; 39(11):1787-1796. PubMed ID: 30181579
[TBL] [Abstract][Full Text] [Related]
16. Role of the soluble guanylyl cyclase alpha1/alpha2 subunits in the relaxant effect of CO and CORM-2 in murine gastric fundus.
De Backer O; Elinck E; Sips P; Buys E; Brouckaert P; Lefebvre RA
Naunyn Schmiedebergs Arch Pharmacol; 2008 Nov; 378(5):493-502. PubMed ID: 18563392
[TBL] [Abstract][Full Text] [Related]
17. Synergistic suppression of prostatic cancer cells by coexpression of both murine double minute 2 small interfering RNA and wild-type p53 gene in vitro and in vivo.
Ji K; Wang B; Shao YT; Zhang L; Liu YN; Shao C; Li XJ; Li X; Hu JD; Zhao XJ; Xu DQ; Li Y; Cai L
J Pharmacol Exp Ther; 2011 Jul; 338(1):173-83. PubMed ID: 21444629
[TBL] [Abstract][Full Text] [Related]
18. Regulation of p53 and MDM2 activity by MTBP.
Brady M; Vlatkovic N; Boyd MT
Mol Cell Biol; 2005 Jan; 25(2):545-53. PubMed ID: 15632057
[TBL] [Abstract][Full Text] [Related]
19. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between MYCN and MDM2-p53 signal pathways regulates tumor cell growth and apoptosis in neuroblastoma.
He J; Gu L; Zhang H; Zhou M
Cell Cycle; 2011 Sep; 10(17):2994-3002. PubMed ID: 21862876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
